RxDoctor Payments Data

Clayton Hudnall, MD

Urology · San Antonio, TXNPI 1952381063

Payments from drug & device makers

$11,133in general payments, 2019–2025

Across 53 payments — averaging $210.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$4K
  • SN Holdings, LLC$3K
  • AstraZeneca$2K
  • Myovant Sciences Inc.$1K
  • Johnson & Johnson$428
  • Merck$255
  • plus $536 from 16 others

What the payments were for

  • Consulting fees$5,12846%
  • Speaking & faculty fees$2,30021%
  • Travel & lodging$1,79416%
  • Food & beverage$1,83016%
  • Education$811%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,133 in reported general payments places this provider in the 75th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$198,335
Medicare patients
744
Services billed
4,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide69$934,407
ErleadaApalutamide14$188,719
MyrbetriqMirabegron120$121,048
Abiraterone Acetate33$99,504
OrgovyxRelugolix20$54,196
GemtesaVibegron29$31,323
Tamsulosin Hcl848$11,145
Mirabegron ErMirabegron14$11,096
Alfuzosin Hcl ErAlfuzosin Hcl464$10,569
Finasteride866$10,223
Dutasteride173$5,177
Potassium Citrate ErPotassium Citrate36$3,257
Estradiol35$2,649
Testosterone Cypionate36$2,342
NitrofurantoinNitrofurantoin Macrocrystal24$899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$53$1,055,455189 claims
Johnson & JohnsonErleada$428$188,71914 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$64$85,51849 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 878 urology providers in Texas.

Other urology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →